$10.63
6.37149.53%
At close: Dec 15, 4:00 PM EST
$6.22
-4.41-41.49%
After Hours: 7:59 PM EST
Comments
Loading...
Radiopharm Theranostics Analyst Ratings and Price Targets | NASDAQ:RADX | Benzinga
Radiopharm Theranostics Ltd has a consensus price target of $14.33 based on the ratings of 3 analysts. The high is $18 issued by Brookline Capital on July 21, 2025. The low is $12 issued by Maxim Group on May 1, 2025. The 3 most-recent analyst ratings were released by B. Riley Securities, Brookline Capital, and Maxim Group on November 26, 2025, July 21, 2025, and May 1, 2025, respectively. With an average price target of $14.33 between B. Riley Securities, Brookline Capital, and Maxim Group, there's an implied 130.44% upside for Radiopharm Theranostics Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B. Riley Securities
Brookline Capital
Maxim Group
1calculated from analyst ratings
Analyst Ratings for Radiopharm Theranostics
FAQ
What is the target price for Radiopharm Theranostics (RADX) stock?
The latest price target for Radiopharm Theranostics (NASDAQ:RADX) was reported by B. Riley Securities on November 26, 2025. The analyst firm set a price target for $13.00 expecting RADX to rise to within 12 months (a possible 109.01% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Radiopharm Theranostics (RADX)?
The latest analyst rating for Radiopharm Theranostics (NASDAQ:RADX) was provided by B. Riley Securities, and Radiopharm Theranostics maintained their buy rating.
When was the last upgrade for Radiopharm Theranostics (RADX)?
There is no last upgrade for Radiopharm Theranostics
When was the last downgrade for Radiopharm Theranostics (RADX)?
There is no last downgrade for Radiopharm Theranostics.
When is the next analyst rating going to be posted or updated for Radiopharm Theranostics (RADX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Radiopharm Theranostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Radiopharm Theranostics was filed on November 26, 2025 so you should expect the next rating to be made available sometime around November 26, 2026.
Is the Analyst Rating Radiopharm Theranostics (RADX) correct?
While ratings are subjective and will change, the latest Radiopharm Theranostics (RADX) rating was a maintained with a price target of $15.00 to $13.00. The current price Radiopharm Theranostics (RADX) is trading at is $6.22, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
